Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine and Methylphenidate for Cognitive Symptoms in TBI and/or PTSD
NCT01416948Phase 2Terminated
- Start
- Aug 2011
- Primary completion
- Mar 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of galantamine, methylphenidate hydrochloride extended-release chewable tablet in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI). Started Aug 2011; status: terminated.
02
Drugs
galantaminemethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
post-traumatic stress disorder (PTSD)traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT01416948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416948.